Biopromic

Biopromic

Uppsala, Sweden· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $1.8M

Overview

Biopromic is focused on creating innovative diagnostic solutions that are both rapid and affordable, targeting the point-of-care market. The company leverages a versatile technology platform designed to address a wide range of diseases, aiming to improve patient outcomes through earlier and more accessible detection. While specific pipeline details and leadership are not publicly disclosed on their website, their mission centers on democratizing diagnostic access. Their strategic direction appears to be the development and commercialization of their core diagnostic platform for various applications.

Diagnostics

Technology Platform

A broad-spectrum technology platform designed to enable rapid and low-cost point-of-care diagnostics across multiple disease areas.

Funding History

1
Total raised:$1.8M
Seed$1.8M

Opportunities

Significant growth opportunity lies in the expanding global point-of-care diagnostics market, particularly in resource-limited settings and decentralized care models where low cost and rapid results are critical.
The platform's claimed versatility allows for potential expansion into multiple disease verticals.

Risk Factors

Key risks include failure to achieve required clinical performance and regulatory approval, intense competition from established diagnostics giants, challenges in manufacturing scale-up, and dependence on securing sufficient funding to reach commercialization.

Competitive Landscape

Competes in the crowded point-of-care diagnostics market against large players like Abbott, Roche, and QuidelOrtho, as well as numerous startups. Potential differentiation is based on combining a versatile platform with a low-cost structure.